China drugmaker begins trial production of AstraZeneca COVID-19 vaccine
SHENZHEN -- A Shenzhen-based drugmaker on Tuesday began trial production of a COVID-19 vaccine from multinational pharmaceutical company AstraZeneca.
Shenzhen Kangtai Biological Products Co. Ltd. announced that it has built a production workshop for the adenovirus vector vaccine developed by AstraZeneca and the University of Oxford, which won the approval for emergency use in the United Kingdom on Dec. 30.
The facility, with a floor area of 2,200 square meters, has an annual production capacity of 400 million doses.
The Shenzhen drugmaker signed a deal with AstraZeneca in August 2020 to introduce the latter's COVID-19 vaccine into China for which it is seeking clinical registration.
The company itself developed an inactivated coronavirus vaccine and is planning to launch phase 3 trials.
- Xi stresses adopting high standards for building Hainan Free Trade Port
- Xizang unboxed: Fresh perspectives
- China's first double-deck cable-stayed suspension bridge opens to traffic over Yangtze
- Southern Ocean releases far more CO2 in winter than previously thought: study
- China-Arab States Forum on Radio and TV opens in Chongqing
- China's Global Mangrove vision takes root in Shenzhen
